Journament

Keyword Connections - multiple sclerosis Keywords

Connection Type	Connection
Journals	the journal of nutrition Medicine Journal of medical Internet research International journal of qualitative studies on health and well-being JAMA pediatrics journal of molecular graphics & modelling Anatolian journal of cardiology the british journal of dermatology European radiology JAMA annals of internal medicine Patient education and counseling medicines (basel, switzerland) neuroimage clinical value in health regional issues medical hypotheses behavioural processes Endocrine clinical neurophysiology : official journal of the international federation of clinical neurophysiology journal of child neurology gait & posture health (london, england : 1997) human gene therapy Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP) Current biology : CB The journal of sexual medicine Digital health therapeutic advances in neurological disorders American journal of ophthalmology clinica chimica acta; international journal of clinical chemistry the journal of endocrinology frontiers in neurology physiological measurement pm & r : the journal of injury, function, and rehabilitation Diagnostics (Basel, Switzerland) turkish journal of physical medicine and rehabilitation clinical neurology and neurosurgery Medical image analysis neuropsychological rehabilitation European Neurology Multiple sclerosis and related disorders journal of molecular medicine (berlin, germany) Anaesthesia journal of neurology acta neurologica scandinavica nutritional neuroscience multiple sclerosis (houndmills, basingstoke, england) journal of neurology, neurosurgery, and psychiatry ACS biomaterials science & engineering neurorehabilitation Handbook of clinical neurology neuroimaging clinics of north america iranian journal of neurology
Research Groups	No Research Group Connected
Bibliographies	[1] Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. [2] Randomized controlled trial of SystemCHANGE™ weight management intervention in neurological conditions. [3] Auditory brainstem response. [4] Self-regulation of brain activity and its effect on cognitive function in patients with multiple sclerosis - First insights from an interventional study using neurofeedback. [5] Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives. [6] Constraint-induced movement therapy in multiple sclerosis: Safety and three-dimensional kinematic analysis of upper limb activity. A randomized single-blind pilot study. [7] The association between gait variability with the energy cost of walking depends on the fall status in people with multiple sclerosis without mobility aids. [8] Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. [9] Association Between Dialysis Facility Ownership and Access to Kidney Transplantation. [10] Alignment independent 3D-QSAR studies and molecular dynamics simulations for the identification of potent and selective S1P receptor agonists. [11] Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. [12] Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait. [13] Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis. [14] Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis. [15] Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. [16] Modern banking, collection, compatibility testing and storage of blood and blood components. [17] Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. [18] Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. [19] Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. [20] Visual Function and Disability are Associated with Increased Retinal Volumetric Vessel Density in Patients with Multiple Sclerosis. [21] Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study. [22] A changed life: The life experiences of patients with psoriasis receiving biological treatment. [23] Self-Reported Changes in Cognition, Communication and Swallowing in Multiple Sclerosis: Data from the Swedish Multiple Sclerosis Registry and from a National Survey. [24] Upper and lower limb performance fatigability in persons with multiple sclerosis investigated through surface electromyography: a pilot study. [25] Herpes viruses in optic neuritis: Similar to Bell's palsy. [26] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia. [27] Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. [28] Reiber's Diagram for Kappa Free Light Chains: The New Standard for Assessing Intrathecal Synthesis? [29] Diagnostic relevance of free light chains in cerebrospinal fluid - The hyperbolic reference range for reliable data interpretation in quotient diagrams. [30] Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset. [31] Adjusting to living with multiple sclerosis: The role of social groups. [32] Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. [33] Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? [34] Fully automated longitudinal segmentation of new or enlarged multiple sclerosis lesions using 3D convolutional neural networks. [35] Neural implant for the treatment of multiple sclerosis. [36] Diverse Applications of Artificial Intelligence in Neuroradiology. [37] sexual therapy for women with multiple sclerosis and its impact on quality of life [38] targeting cognitive impairment in multiple sclerosis—the road toward an imaging-based biomarker [39] dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations [40] impact of natalizumab treatment on fatigue, mood and aspects of cognition in relapsing-remitting multiple sclerosis [41] guardian ad litem, a potentially expensive invitation to either the mismanagement or management of patients with cognitive disorders [42] magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients [43] paroxysmal dysphasia in a 68 year-old man: enhancing the mri spectrum! [44] effect of combined mental and physical training on the targeting accuracy of patients with multiple sclerosis [45] b cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions [46] exploring the role of microglia in mood disorders associated with experimental multiple sclerosis [47] [48] differential expression of <i>smad</i> genes and <i>s1pr1</i> on circulating cd4+ t cells in multiple sclerosis and crohn’s disease [49] polymorphism of apo lipoprotein e gene and the risk of multiple sclerosis [50] evaluation of visual-evoked cerebral metabolic rate of oxygen as a diagnostic marker in multiple sclerosis [51] the physicochemical and thermodynamic properties of the choline chloride-based deep eutectic solvents [52] cerebellar dysfunction in multiple sclerosis [53] motor evoked potentials modification in different forms and stages of multiple sclerosis [54] a new method for segmentation of multiple sclerosis (ms) lesions on brain mr images [55] quality of life, coping, and social support in patients with multiple sclerosis: a pilot study [56] the evaluation of serum testostrone level in reproductive age women with multiple sclerosis and its relation with disease severity [57] regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant [58] immunological markers for pml prediction in ms patients treated with natalizumab [59] understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the alemtuzumab clinical development program [60] structural networks involved in attention and executive functions in multiple sclerosis [61] determination of soluble icam-1 and tnfalphar in the cerebrospinal fluid and serum levels in a population of brazilian patients with relapsing-remitting multiple sclerosis determinação dos níveis de icam-1 e tnfalfar solúvel no líquido cefalorraqueano e soro numa população de pacientes brasileiros com esclerose múltipla forma surto-remissão [62] characterization of the first symptoms of multiple sclerosis in a brazilian center: cross-sectional study [63] a study of psychological well-being in people with multiple sclerosis and their primary caregivers [64] the representation of inflammatory signals in the brain – a model for subjective fatigue in multiple sclerosis [65] psychiatric disorders in multiple sclerosis patients transtornos psiquiátricos em pacientes com esclerose múltipla [66] repopulation of t, b, and nk cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis [67] the role of information system in multiple sclerosis management [68] ccl5–glutamate cross-talk in astrocyte-neuron communication in multiple sclerosis [69] analysis of plasminogen genetic variants in multiple sclerosis patients [70] investigating negotiated treatment goals as a tool to facilitate collaboration between conventional and complementary practitioners in the treatment of people with multiple sclerosis [71] development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment [72] corrigendum: high-resolution spectral domain-optical coherence tomography in multiple sclerosis, part ii - the total macular volume. the first follow-up study over 2 years. [73] multiple sclerosis and the comparative value disease modifying therapy report of the institute for clinical and economic review (icer) [74] understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models [75] mental toughness, sleep disturbances, and physical activity in patients with multiple sclerosis compared to healthy adolescents and young adults [76] matrix metalloproteinases, synaptic injury, and multiple sclerosis [77] the role of t1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis [78] 1,25-dihydroxyvitamin d3 conditioned cd11c+ dendritic cells are effective initiators of cns autoimmune disease [79] oligoclonal igg bands in the cerebrospinal fluid of portuguese patients with multiple sclerosis: negative results indicate benign disease bandas oligoclonais da igg no líquido céfalo-raquidiano de doentes portugueses com esclerose múltipla: resultados negativos indicam doença benigna [80] successful treatment for psychomotor agitation in neuromyelitis optica spectrum disorder with trazodone–risperidone combination: a case report [81] new multiple sclerosis disease severity scale predicts future accumulation of disability [82] jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis [83] serum levels of brain-derived neurotrophicfactor correlate with the number of t2 mri lesions in multiple sclerosis [84] suppression of inflammatory demyelinaton and axon degeneration through inhibiting kv3 channels [85] diffusion tensor imaging of the cervical spinal cord of patients with relapsing-remising multiple sclerosis: a study of 41 cases imagens por tensor de difusão da medula cervical de pacientes com esclerose múltipla remitente-recorrente: estudo de 41 casos [86] prolactin and autoimmunity [87] therapeutic inertia in the new landscape of multiple sclerosis care [88] long-term change in central corneal thickness from a glaucoma perspective [89] brain mri in patients with multiple sclerosis with oligoclonal cerebrospinal fluid bands [90] cytokines stimulate the release of microvesicles from myeloid cells independently from the p2x7 receptor/acid sphingomyelinase pathway [91] the contribution of optical coherence tomography in neuromyelitis optica spectrum disorders [92] difference in motor fatigue between patients with stroke and patients with multiple sclerosis: a pilot study [93] polyunsaturated fatty acids for multiple sclerosis treatment [94] myelin basic protein and a multiple sclerosis-related mbp-peptide bind to oligonucleotides [95] myeloid extracellular vesicles: messengers from the demented brain [96] update on riboflavin and multiple sclerosis: a systematic review [97] manifestações oculares em pacientes com esclerose múltipla em são paulo ocular manifestations in patients with multiple sclerosis in são paulo [98] monosodium urate crystals activate the inflammasome in primary progressive multiple sclerosis [99] is there an increased risk for ischemic stroke in patients with multiple sclerosis, and if so, should preventive treatment be considered? [100] dopaminergic stimulation of myeloid antigen-presenting cells attenuates signal transducer and activator of transcription 3-activation favouring the development of experimental autoimmune encephalomyelitis [101] circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: a case-control study